35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective To evaluate the association between door-to-balloon time and mortality in hospital in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction to assess the incremental mortality benefit of reductions in door-to-balloon times of less than 90 minutes.

          Design Prospective cohort study of patients enrolled in the American College of Cardiology National Cardiovascular Data Registry, 2005-6.

          Setting Acute care hospitals.

          Participants 43 801 patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.

          Main outcome measure Mortality in hospital.

          Results Median door-to-balloon time was 83 minutes (interquartile range 6-109, 57.9% treated within 90 minutes). Overall mortality in hospital was 4.6%. Multivariable logistic regression models with fractional polynomial models indicated that longer door-to-balloon times were associated with a higher adjusted risk of mortality in hospital in a continuous non-linear fashion (30 minutes=3.0%, 60 minutes=3.5%, 90 minutes=4.3%, 120 minutes=5.6%, 150 minutes=7.0%, 180 minutes=8.4%, P<0.001). A reduction in door-to-balloon time from 90 minutes to 60 minutes was associated with 0.8% lower mortality, and a reduction from 60 minutes to 30 minutes with a 0.5% lower mortality.

          Conclusion Any delay in primary percutaneous coronary intervention after a patient arrives at hospital is associated with higher mortality in hospital in those admitted with ST elevation myocardial infarction. Time to treatment should be as short as possible, even in centres currently providing primary percutaneous coronary intervention within 90 minutes.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: not found
          • Article: not found

          CIRCULATION

          SS Chugh (1964)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction.

            We sought to determine the effect of door-to-balloon time on mortality for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Studies have found conflicting results regarding this relationship. We conducted a cohort study of 29,222 STEMI patients treated with PCI within 6 h of presentation at 395 hospitals that participated in the National Registry of Myocardial Infarction (NRMI)-3 and -4 from 1999 to 2002. We used hierarchical models to evaluate the effect of door-to-balloon time on in-hospital mortality adjusted for patient characteristics in the entire cohort and in different subgroups of patients based on symptom onset-to-door time and baseline risk status. Longer door-to-balloon time was associated with increased in-hospital mortality (mortality rate of 3.0%, 4.2%, 5.7%, and 7.4% for door-to-balloon times of 150 min, respectively; p for trend 90 min had increased mortality (odds ratio 1.42; 95% confidence interval [CI] 1.24 to 1.62) compared with those who had door-to-balloon time 1 to 2 h, >2 h) and regardless of the presence or absence of high-risk factors. Time to primary PCI is strongly associated with mortality risk and is important regardless of time from symptom onset to presentation and regardless of baseline risk of mortality. Efforts to shorten door-to-balloon time should apply to all patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.

              In this study we assessed the long-term efficacy and safety of disopyramide for patients with obstructive hypertrophic cardiomyopathy (HCM). It has been reported that disopyramide may reduce left ventricular outflow gradient and improve symptoms in patients with HCM. However, long-term efficacy and safety of disopyramide has not been shown in a large cohort. Clinical and echocardiographic data were evaluated in 118 obstructive HCM patients treated with disopyramide at 4 HCM treatment centers. Mortality in the disopyramide-treated patients was compared with 373 obstructive HCM patients not treated with disopyramide. Patients were followed with disopyramide for 3.1 +/- 2.6 years; dose 432 +/- 181 mg/day (97% also received beta-blockers). Seventy-eight patients (66%) were maintained with disopyramide without the necessity for major non-pharmacologic intervention with surgical myectomy, alcohol ablation, or pacing; outflow gradient at rest decreased from 75 +/- 33 to 40 +/- 32 mm Hg (p /=3 years. Disopyramide therapy does not appear to be proarrhythmic in HCM and should be considered before proceeding to surgical myectomy or alternate strategies.
                Bookmark

                Author and article information

                Contributors
                Role: MD/PhD student
                Role: assistant professor
                Role: assistant professor
                Role: statistician
                Role: assistant professor
                Role: assistant professor
                Role: Harold H Hines Jr professor of medicine (cardiology) and epidemiology and public health
                Journal
                BMJ
                bmj
                BMJ : British Medical Journal
                BMJ Publishing Group Ltd.
                0959-8138
                1468-5833
                2009
                2009
                19 May 2009
                : 338
                : b1807
                Affiliations
                [1 ]MD/PhD Program, Yale University School of Medicine, 367 Cedar Street, 316 ESH, New Haven, Connecticut 06510
                [2 ]Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, 3 FMP, PO Box 208017, New Haven, Connecticut 06520
                [3 ]Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, One Church Street, Suite 200, New Haven, Connecticut 06510
                [4 ]Cardiovascular Center, CVC Cardiovascular Medicine, University of Michigan Medical School, SPC 5869, 1500 E Medical Center Drive, Ann Arbor, Michigan 48109
                [5 ]Section of Health Policy and Administration, Yale School of Public Health, 60 College Street, Room 301, PO Box 208034, New Haven, Connecticut 06520
                [6 ]Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, PO Box 208088, New Haven, Connecticut 06520
                Author notes
                Correspondence to: S S Rathore saif.rathore@ 123456yale.edu
                Article
                rats605337
                10.1136/bmj.b1807
                2684578
                19454739
                3c136952-5cba-457d-8a93-9c578c904fce
                © Rathore et al 2009

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 January 2009
                Categories
                Research
                Epidemiologic Studies
                Drugs: Cardiovascular System
                Stroke
                Interventional Cardiology
                Ischaemic Heart Disease
                Cardiothoracic Surgery
                Vascular Surgery

                Medicine
                Medicine

                Comments

                Comment on this article

                scite_

                Similar content213

                Cited by104

                Most referenced authors456